A5011395838- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Attention Deficit Hyperactivity Disorder
- Prostate Cancer Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
- Child and Adolescent Psychosocial and Emotional Development
- Radiopharmaceutical Chemistry and Applications
- Cognitive Abilities and Testing
- Cancer Cells and Metastasis
- CRISPR and Genetic Engineering
National Cancer Institute
2017-2024
University of California, San Francisco
2023-2024
National Institutes of Health
2019
Cancer Institute (WIA)
2019
Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies significant disease before treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely to harbor aggressive disease.
Localized prostate cancer develops very slowly in most men, with the androgen receptor (AR) and MYC transcription factors amongst well-characterized drivers of tumorigenesis. Canonically, up-regulation luminal cells functions to oppose terminally differentiating effects AR. However, are pleiotropic inconsistent a poorly proliferative phenotype. Here we show that increased expression activity associated down-regulation MEIS1, HOX-family factor. Using RNA-seq profile series human specimens...
ABSTRACT Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies significant disease prior to treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely harbor aggressive disease. applied ultra-low pass whole genome sequencing profile cell-free from 112 localized cancer and performed targeted resequencing plasma somatic mutations...
Attention deficit hyperactivity disorder (ADHD) affects about 13% of adolescents and is associated with substance use-related morbidity mortality. While evidence on effective interventions to reduce alcohol use among ADHD limited, parent-teen communication has been found be protective. Other approaches, such as educational interventions, hold promise alcohol-related harms in ADHD. Digital technology offers an innovative approach health behavior change, expanding access services may promote...
Abstract Human cancer tissues are known to release their own DNA into body fluids such as plasma. These molecules derived from tumors, collectively circulating tumor (ctDNA), contain genetic information about disease progression at the time of sampling. Importantly, ctDNA has recently been utilized for capturing whole-body profile and when sampled various points over treatment, can inform dynamic clonal heterogeneity its contribution therapy failures. Metastatic castration-resistant prostate...
Abstract Background: Molecular characterization of mCRPC has revealed disruption DNA damage repair genes that may improve sensitivity to PARP inhibitors such as olaparib (O), which in turn further complement the activity PD-L1 immune checkpoint inhibitor, durvalumab (D), through mechanisms activation STING pathway. We hypothesized (epi)genomic analyses circulating tumor (ctDNA) would identify treatment response patients with treated O plus D (NCT02484404). Methods: Eligible for this study...
Abstract Cancer cells secrete fragments of their genetic material in the form cell-free DNA (cfDNA) producing a potential biomarker for following cell growth and drug response. While cfDNA has been popularized as liquid biopsy analyte monitoring disease status patients with metastases, we have also applied detection vitro establishment patient-derived organoid cancer lines. Because diversity tumor subtypes many cancers requires extensive optimization, combinations factors or other...
34 Background: AR directed therapies are standard of care for metastatic prostate cancer, and their use high-risk localized disease may improve survival. Previous trials showed low rates complete pathologic responses to neoadjuvant ADT. The underlying biology molecular features tumors that fail respond remain unknown. Methods: Men with cancer high risk received 6 months GnRH agonist plus enzalutamide. mpMRI was performed at baseline prior RP. MRI-US fusion guided biopsies were study...
Background and HypothesisCancer cells release circulating tumor DNA (ctDNA) into the bloodstream, which has potential to be clinically relevant as a marker of clonality clinical response. This
ABSTRACT Localized prostate cancer develops very slowly in most men, with the androgen receptor (AR) and MYC transcription factors amongst well-characterized drivers of tumorigenesis. Canonically, up-regulation luminal cells functions to oppose terminally differentiating effects AR. However, are pleiotropic inconsistent a poorly proliferative phenotype. Here we show that increased expression activity associated down-regulation MEIS1 , HOX-family factor. Using RNA-seq profile series human...
342 Background: The differential aggressiveness of potentially independent prostate cancer clones remains largely unknown. Appropriate staging using mpMRI and biopsy tissue can be confounded by sampling error. To date, there has been no understanding whether clonal variability influences management decisions for localized tumors. We sought to identify the sensitivity genomic profile distinct tumors from a patient following systemic intense neoadjuvant androgen deprivation therapy (ADT)....